Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALD-102 in Alopecia Areata
NCT06826196Phase 2Active, not recruiting
- Sponsor
- Aldena Therapeutics
- Start
- Mar 2025
- Primary completion
- Nov 2026
- Countries
- 2
01
Overview
A Phase 2 trial of elivaldogene autotemcel in alopecia areata, sponsored by Aldena Therapeutics. Started Mar 2025; status: active, not recruiting.
02
Drugs
elivaldogene autotemcel
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT06826196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06826196.